Made Scientific, the Princeton-based cell therapy manufacturing company, announced Thursday the launch of its scientific advisory board with four members being appointed: Miguel Forte, Paul Wotton, Shishir Gadam and Young Hong.
The board will be responsible for providing strategic guidance in hopes of reinforcing the CDMO platform and accelerating innovation. Among these aspirations include lowering the cost of goods for cell therapies, and enabling partners to deliver more accessible, reliable, and transformative therapies to patients globally.
Among the four members:
- Miguel Forte – CEO of Kiji Therapeutics and President of the International Society for Cell and Gene Therapy. Forte also served at the European Medicines Agency and has leadership roles with the Alliance for Regenerative Medicine.
- Paul Wotton – CEO of RBL LLC, a Houston-based biotech accelerator, and executive director of the Biotech Launch Pad at Rice University. Wotton also serves on the boards of Vericel Corporation, Cynata Therapeutics, Morphocell Technologies, and Combined Therapeutics.
- Shishir Gadam – Chief technical officer at Marea Therapeutics and former head of Technical Operations at Cargo Therapeutics, where he built manufacturing infrastructure and advanced novel CAR-T programs. Gadam also had earlier roles in biologics development at Genentech and Roche.
- Young Hong – is a dual board-certified general surgeon and surgical oncologist/hepatopancreatobiliary surgeon at Cooper University Hospital and MD Anderson Cancer Center at Cooper. He serves as Director of Clinical Research and Cellular Therapy, Assistant Director of Surgical Research, and Director of the Surgical Outcomes Research Group.
Made Scientific CEO Syed Husain explained their experience and his hopes for the company.
“The establishment of our Scientific Advisory Board marks a pivotal moment in our commitment to innovation,” he said. “Miguel, Paul, Shishir, and Young each bring world-class expertise across cell therapy, manufacturing science, commercialization, and clinical practice that will directly shape our service priorities, ensuring we deliver solutions for patients globally.”
